Nohla Therapeutics is a leading developer of off-the shelf cell therapies for patients with cancer and other critical diseases. Nohla’s proprietary notch ligand technology platform serves as the foundation for its ongoing clinical, preclinical and discovery programs. The company’s lead product candidate, dilanubicel (NLA101), is currently being evaluated in two ongoing Phase 2 trials for patients with hematologic malignancies undergoing a myeloablative allogeneic transplant, and acute myeloid leukemia (AML) patients with chemotherapy-induced myelosuppression following high-dose chemotherapy. Nohla is also pursuing multiple preclinical and discovery programs in the areas of autoimmunity and other diseases.

Contact Nohla Therapeutics
nfo@nohlatherapeutics.com
Jim DeNike Senior Director, Corporate Development & Investor Relations 206-519-5294
Visit Website